Abstract:Among the best-established causal risk factors for cardiovascular disease is the blood concentration of low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), an antagonist to the LDL receptor, has emerged as a promising therapeutic target for the prevention of coronary heart disease. Current PCSK9 inhibitors are administered via subcutaneous injection, and their effects are short-lived. An alternative “one-and-done” strategy using genome editing to disrupt PCSK9 at the DNA level has been demonstrated in preclinical animal models, including non-human primates. However, concerns about the permanence and irreversibility of the genomic changes have been raised and might limit the acceptance of the therapies. Recently, a set of CRISPR-based epigenome editing tools, CRISPRoff and CRISPRon, were reported to regulate gene expression via site-directed methylation and demethylation of gene promoters, respectively. We hypothesized that these epigenome editing tools could durably and reversibly induce methylation changes in the PCSK9 promoter and thereby modulate its expression. We first screened CRISPRoff guide RNAs (gRNAs) targeting the PCSK9 promoter, individually and in dual combinations, for their ability to reduce PCSK9 expression in the human HuH-7 hepatoma cell line. We then performed long-term experiments with the lead candidate gRNAs. We found that these CRISPRoff gRNAs induced profound increases in methylation at CpG dinucleotides in the PCSK9 promoter, with up to 80% decreases in PCSK9 expression. These methylation increases and gene expression decreases have endured through >56 cell divisions so far, with only mild attenuation over time. Using the same gRNAs with CRISPRon in cells previously treated with CRISPRoff, we observed moderate decreases in methylation and increases in PCSK9 expression. Having established these effects in vitro , we are similarly assessing the durability and reversibility of epigenome editing using the lead gRNAs in a PCSK9 -humanized mouse model. Overall, this work provides a proof of concept of precise gene regulation via methylation and demethylation and suggests a potential new therapeutic approach for protection against coronary heart disease.

CHARM and EvoETR: Precision epigenetic tools for gene silencing

Durable and efficient gene silencing in vivo by hit-and-run epigenome editing

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins

Epigenome editing for targeted DNA (de)methylation: a new perspective in modulating gene expression

Fine-Tuning the Epigenetic Landscape: Chemical Modulation of Epigenome Editors

Regulation of gene expression by altered promoter methylation using a CRISPR/Cas9-mediated epigenetic editing system

Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies

All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders

Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor

Abstract 125: Reversible Epigenome Editing Of PCSK9 As A Therapeutic Strategy

Advances in CRISPR-Cas systems for epigenetics

Two Compact Cas9 Ortholog-Based Cytosine Base Editors Expand the DNA Targeting Scope and Applications In Vitro and In Vivo

Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing

Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges.

Tailoring a CRISPR/Cas-based Epigenome Editor for Programmable Chromatin Acylation and Decreased Cytotoxicity

Precision epigenetic editing: Technological advances, enduring challenges, and therapeutic applications

CRISPR/dCas9-Tet1-Mediated DNA Methylation Editing.

CRISPR-Cas9 DNA Base-Editing and Prime-Editing

Prime editing for precise and highly versatile genome manipulation

Rational Design of Enhanced Nme2Cas9 and Nme2 Cas9 Nucleases and Base Editors